Related Experiment Videos
Prophylaxis of experimental HTLV-I infection in cynomolgus monkeys by passive immunization
1Tsukuba Primate Center for Medical Science, National Institute of Health, Ibaraki, Japan.
Vaccine
|August 1, 1997
Abstract:
The protective effect of purified human immunoglobulin against human T-cell leukaemia virus type I (HTLV-I), designated ATLIG on HTLV-I infection was examined in cynomolgus monkeys (Macaca fascicularis) as a preclinical study. Passive immunization of ATLIG 24 h before challenging HTLV-I protected the monkeys from HTLV-I infection. The result suggests that passive immunization of ATLIG could provide safe and sufficient protection against HTLV-I infection in humans.